Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC pediculicides

This article was originally published in The Tan Sheet

Executive Summary

FDA announces availability of "background documents" related to the agency's response to two NDMA petitions on the regulation of pediculicides in a Dec. 6 Federal Register notice. In December 1993, FDA published a final rule that announced that FDA would assume the Environmental Protection Agency's role in regulating pediculicides. After NDMA requested a one-year extension of the Dec. 14, 1994 effective date for complying with FDA (and not EPA) labeling requirements for anti-lice products, FDA told the association that extensions would be granted on a case-by-case basis only ("The Tan Sheet" June 27, p. 14). The agency said it is making its correspondence with NDMA publicly available "to ensure that all interested persons are aware of the issues that were raised" by NDMA

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel